$1.24
10.71% yesterday
Nasdaq, Jul 17, 10:10 pm CET
ISIN
US29664W1053
Symbol
ESPR
Sector
Industry

Esperion Therapeutics, Inc. Stock price

$1.24
+0.15 13.76% 1M
-0.97 43.89% 6M
-0.96 43.64% YTD
-1.38 52.67% 1Y
-5.26 80.92% 3Y
-46.96 97.43% 5Y
-97.67 98.75% 10Y
-13.26 91.45% 20Y
Nasdaq, Closing price Thu, Jul 17 2025
+0.12 10.71%
ISIN
US29664W1053
Symbol
ESPR
Sector
Industry

Key metrics

Basic
Market capitalization
$222.0m
Enterprise Value
$400.3m
Net debt
$178.4m
Cash
$114.6m
Shares outstanding
196.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 0.6
EV/Sales
1.5 | 1.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
13.3%
ROCE
-178.8%
ROIC
-125.5%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$259.6m | $349.4m
EBITDA
$-94.8m | $-10.3m
EBIT
$-94.9m | $23.8m
Net Income
$-153.2m | $-38.0m
Free Cash Flow
$-100.4m
Growth (TTM | estimate)
Revenue
13.0% | 5.2%
EBITDA
-173.9% | -118.9%
EBIT
-173.4% | -56.2%
Net Income
-77.1% | 26.6%
Free Cash Flow
-266.6%
Margin (TTM | estimate)
Gross
65.3%
EBITDA
-36.5% | -2.9%
EBIT
-36.6%
Net
-59.0% | -10.9%
Free Cash Flow
-38.7%
More
EPS
$-0.8
FCF per Share
$-0.5
Short interest
12.2%
Employees
304
Rev per Employee
$1.1m
Show more

Is Esperion Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Esperion Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

10x Buy
71%
3x Hold
21%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

Buy
71%
Hold
21%
Sell
7%

Financial data from Esperion Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
260 260
13% 13%
100%
- Direct Costs 90 90
116% 116%
35%
170 170
10% 10%
65%
- Selling and Administrative Expenses 164 164
6% 6%
63%
- Research and Development Expense 45 45
33% 33%
17%
-95 -95
174% 174%
-37%
- Depreciation and Amortization 0.09 0.09
13% 13%
0%
EBIT (Operating Income) EBIT -95 -95
173% 173%
-37%
Net Profit -153 -153
77% 77%
-59%

In millions USD.

Don't miss a Thing! We will send you all news about Esperion Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Esperion Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
17 days ago
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience
Positive
Seeking Alpha
about one month ago
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, ...
Neutral
GlobeNewsWire
2 months ago
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to...
More Esperion Therapeutics, Inc. News

Company Profile

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Head office United States
CEO Sheldon Koenig
Employees 304
Founded 1998
Website www.esperion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today